Treatment of Retroperitoneal Fibrosis in IgG4-Related Disease with Ureteral Obstruction
This protocol covers the management of retroperitoneal fibrosis in the specific context of idiopathic retroperitoneal fibrosis and IgG4-related disease, where ureteral obstruction is the central complication requiring a defined treatment approach.
Clinical Scenario
Idiopathic retroperitoneal fibrosis is frequently part of the IgG4-related disease spectrum. In this population, ureteral obstruction is the key clinical complication that drives the urgency of management decisions, with treatment goals oriented toward both relieving obstruction and protecting renal function.
Treatment Approach
In selected patients with this presentation, a surgical intervention targeting the ureteral obstruction is among the approaches that may be considered — the specific procedure, its indications, and the complete clinical decision pathway are available in the full protocol.
Treatment Goals
- Resolution of ureteral obstruction
- Preservation of renal function
References
DOI: 10.1111/iju.14218
- Currently, most idiopathic RPF is considered to be a part of this disease spectrum.
- In IgG4RD, the serum IgG4 level is helpful to control the dosage of glucocorticoid.
- Generally, in idiopathic RPF causing ureteral obstruction, a good outcome for renal function is expected, although long-term steroid therapy along with urinary drainage is often required.
- In contrast, aggressive surgical treatment, such as ureterolysis, can achieve the goal; however, the procedure is associated with high morbidity.
- In contrast, ureterolysis, an aggressive surgical treatment, is carried out to relieve ureteral obstruction and salvage renal function in selected patients, but the optimal indication for it is controversial.
- The goal of treatment for retroperitoneal fibrosis should be freedom from the stent/nephrostomy with withdrawal of the glucocorticoid in addition to salvage of renal function; however, conservative management does not always provide favorable outcomes.